vonoprazan (Voquezna) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori. It is a potassium-competitive acid blocker.   Wikipedia

More Chemistry

Combination drugs

( amoxicillin, vonoprazan (Voquezna) )
|
( amoxicillin, vonoprazan (Voquezna), clarithromycin (biaxin) - other names: vonoprazan, amoxicillin, and clarithromycin, vonoprazan+amoxicillin+clarithromycin 14 days, vonoprazan+amoxicillin+clarithromycin 7 days )
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine | tak438 | tak 438 | tak-438 | takecab | vonoprazan | vonoprazan fumarate

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue